Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
Patnaik A, Tolcher A, Papadopoulos KP, Beeram M, Rasco D, Werner TL, Bauman JW, Scheuber A, Cox DS, Patel BR, Zhou Y, Hamid M, Schramek D, Sharma S. Patnaik A, et al. Among authors: werner tl. Cancer Chemother Pharmacol. 2016 Sep;78(3):491-500. doi: 10.1007/s00280-016-3090-y. Epub 2016 Jul 8. Cancer Chemother Pharmacol. 2016. PMID: 27392790 Clinical Trial.
First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. Munster P, et al. Among authors: werner tl. Clin Cancer Res. 2016 Apr 15;22(8):1932-9. doi: 10.1158/1078-0432.CCR-15-1665. Epub 2015 Nov 24. Clin Cancer Res. 2016. PMID: 26603258 Clinical Trial.
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, D'Amelio AM Jr, Ellis C, Ibrahim N, Yan L. Tolcher AW, et al. Among authors: werner tl. Cancer Chemother Pharmacol. 2020 Apr;85(4):673-683. doi: 10.1007/s00280-020-04038-8. Epub 2020 Feb 15. Cancer Chemother Pharmacol. 2020. PMID: 32062691 Free article. Clinical Trial.
A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker.
Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ. Kelley KC, et al. Among authors: werner tl. BMC Cancer. 2021 May 7;21(1):510. doi: 10.1186/s12885-021-08242-4. BMC Cancer. 2021. PMID: 33957901 Free PMC article. Clinical Trial.
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.
Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Diamond JR, et al. Among authors: werner tl. Invest New Drugs. 2015 Jun;33(3):691-9. doi: 10.1007/s10637-015-0236-4. Epub 2015 Apr 21. Invest New Drugs. 2015. PMID: 25895965 Clinical Trial.
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.
Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS. Garrido-Laguna I, et al. Among authors: werner tl. Int J Cancer. 2019 Oct 1;145(7):1798-1808. doi: 10.1002/ijc.32154. Epub 2019 Feb 23. Int J Cancer. 2019. PMID: 30680712 Free PMC article. Clinical Trial.
84 results